Data Architecture Takes Center Stage As Enterprises Build For Production-Ready AI

Three years into the AI wave, most enterprises have the models, the budget, and the executive mandate. What they don't have is data that's ready for production.

That tension ran through five back-to-back segments on Bloomberg Businessweek Radio, recorded live at Everpure's Accelerate summit in Las Vegas in June 2026. The executives and practitioners who sat down with anchors Carol Massar and Tim Stenovec came from different vantage points: enterprise architecture, product development, R&D, pharmaceutical operations, finance. But across roughly 100 minutes of broadcast, the same diagnosis kept resurfacing. The bottleneck isn't models, and it isn't compute. It's the data.

The readiness gap in numbers

The Bloomberg segments gave voice to a pattern the data validates at scale. A 2026 readiness index from Fivetran, based on a survey of 400 data professionals, found that only 15% of organizations are fully prepared to deploy agentic AI in production, even as nearly 60% report investing millions. A separate Deloitte study found that 42% of companies believe their strategy is prepared for AI adoption, but feel less prepared on infrastructure, data, and risk than they did a year ago. The gap between investment and readiness is widening, not closing.

Rob Lee, Everpure's Chief Technology and Growth Officer, framed the problem as architectural. The enterprise was built in an era where compute was assigned to applications, and data sat behind those applications in silos. AI, and agentic AI in particular, demands a fundamentally different arrangement. "To make agents effective, you have to make those decisions in real time," Lee told Bloomberg's hosts. "The only way you're going to do that is through a data primacy model where you can get the applications out of the way and work on the data directly."

It's a point that resonates beyond the storage industry. Organizations that built their technology stacks around hundreds or thousands of discrete applications now face a structural problem: the data those applications generate and consume is fragmented, contextually isolated, and ungoverned at the pace AI requires. When a human worker encounters inconsistent data, they pause, ask questions, find a workaround. An AI agent does none of that. It ingests what it receives and executes.

Raw materials before machinery

Shawn Rosemarin, Everpure's Global VP of R&D and Customer Engineering, offered what was arguably the broadcast's most durable framing. He described the emerging class of AI-driven infrastructure as "AI factories," and argued that most organizations are approaching them in the wrong order. They're selecting machinery (models, GPUs, cloud services) before confirming they have the raw materials (clean, contextualized, accessible data) to produce anything useful.

The factory metaphor reframes the ROI conversation that has intensified across the enterprise since late 2025. If data is the raw material and AI is the production line, then the bottleneck isn't the factory's output capacity. It's whether the inputs are fit for purpose.

Rosemarin connected this directly to operational economics. "I want to minimize token usage because ultimately I am moving to a price per token. I want to maximize inference," he said. When data is properly indexed, vectorized, and enriched with context, models need less input to produce better output. The cost structure improves, latency drops, and the gap between a prototype and a production-grade system gets narrower.

The inflection point, as Rosemarin described it, is the shift from experimentation to production at scale. "We're now seeing organizations taking those solutions, those prototypes, and wanting to roll them into production. And then the question becomes: is it affordable? Is it manageable?"

What production AI looks like in pharma

The most concrete answer came from outside Everpure's own ranks. Pradeep Bandaru, Head of Platforms and AI Workflows at Sanofi, described what it takes to operationalize AI in an environment where the data is among the most heterogeneous in any industry.

Pharmaceutical data spans sequencing reads, cryo-EM videos, pathology images, manufacturing process records, and lab telemetry. These artifacts are produced by different instruments, stored in different systems, and described by different metadata schemas. AI can't operate on this data until it's captured, contextualized, and structured into something models can traverse. At Sanofi, that means building a pipeline that runs from real-time lab telemetry through a semantic knowledge graph to vectorization, indexing, and inference.

"The data that we work with is incredibly heterogeneous, and it has a lot of metadata that needs to be captured and contextualized in order to make AI actually work," said Bandaru. The payoff, though, is measurable. Drug discovery timelines that historically spanned years are compressing to months. "AI really has proven out its value in understanding the search space for new drug molecules. That's one of the most powerful applications of AI we've seen so far."

The pharma use case is instructive beyond life sciences. The challenge Bandaru described, where data exists in volume but lacks the contextual connections that make it usable, is a version of the same problem every enterprise faces. Context, not volume, is what separates stored data from decision-grade data.

Shared context as an architectural requirement

Chadd Kenney, Everpure's VP of Product Development, narrowed the diagnosis further during his segment. The shift to agentic workflows raises the bar because agents don't just consume data from one system. They need context drawn from across the enterprise: supply chain, manufacturing cost, quoting, approvals. That context is currently siloed in separate applications and stitched together by human judgment. "These agents only effectively execute with consistent shared context," he said. "People are realizing: while the power is there, the data is not ready for this, and they need that shared context."

He also flagged a governance problem that intensifies as agentic adoption accelerates. Organizations are connecting agents directly to applications without security or governance frameworks in place. A shared context model, by contrast, creates a layer where access controls and governance policies can be applied before agents act on data. The alternative is a sprawl of ungoverned agent-to-application connections, each one a potential exposure point.

Kenney also addressed the velocity of change that makes architectural agility essential. "AI, pretty much every six months, is a completely different world. You have to build a framework that's super agile and can move with you. You definitely don't want to lock yourself into a corner." For data leaders evaluating infrastructure investments, the implication is that flexibility matters as much as performance. A platform that locks an organization into a fixed architecture today may not accommodate the workflows AI demands six months from now.

The investment scale behind the readiness question

Tarek Robbiati, Everpure's CFO, placed the data readiness challenge inside a financial frame that resonated with Bloomberg's investor audience. The cumulative capital expenditure of the hyperscalers alone is projected at roughly $3 trillion over the next three years, a figure Robbiati noted is about two times the U.S. defense budget. That estimate excludes the AI-native companies (Anthropic, OpenAI, Cohere) and neocloud providers (CoreWeave, Crusoe). The investment is significant, and it's accelerating.

But capital alone doesn't produce returns. Robbiati pointed to a "flight to quality" among enterprises facing sharp component price increases, arguing that when budgets are under pressure, organizations converge toward platforms that will endure. "If you invest today, choose carefully and choose the best possible product from a quality standpoint. One that will stand the test of time," he said. The structural supply constraints in NAND and DRAM, driven by the same AI demand that's fueling the CapEx supercycle, make infrastructure decisions harder to reverse and more consequential to get right.

The financial picture reinforces the readiness argument from a different angle. If the industry is pouring trillions into AI infrastructure, the organizations that capture returns will be the ones whose data layers can actually absorb and operationalize that investment. Compute without data readiness is, as Everpure executive Kaycee Lai has described it, like buying a race car and parking it in rush hour traffic.

From experiments to evidence

The consistency of the diagnosis across the five Bloomberg segments, from practitioners operating at very different altitudes, points to something concrete. The enterprise AI market is crossing a threshold where the constraint isn't ambition, models, or capital. It's whether the data foundation can support what the technology is now capable of doing.

Sanofi's production pipeline offers early evidence that it can. Drug discovery timelines measured in years are compressing to months. Real-time lab telemetry flows through a semantic knowledge graph into model training and inference. The loop is closing, and it's closing faster as context accrues.

For data leaders watching the market, the signal from Las Vegas is unmistakable. Increasing the model budget won't cut it. For an organization to truly lead, they must invest in the data layer first, build shared context across their systems, and treat AI readiness as an infrastructure commitment rather than a mere technology experiment.